Loading chat...
NY A10479
Bill
Status
Introduced
5/29/2024
Primary Sponsor
Jacob Blumencranz
Click for details
AI Summary
- Requires pharmacy benefit managers to disclose to health plans, pharmacies, and patients whether prescription drugs were manufactured or compounded in foreign countries
- Mandates disclosure of whether drugs were approved by the federal Food and Drug Administration foreign drug inspection program and the date of the last FDA inspection
- Requires prescription drug labels to include country of manufacture or compounding, FDA foreign drug inspection program approval status, and last inspection date
- Specifies that labels must be highlighted in yellow or bold type (minimum 12-point font), with unapproved drugs requiring a warning sign and 14-point minimum font
- Takes effect immediately upon enactment
Legislative Description
Enacts the "foreign drug transparency act"; requires the disclosure to a health plan, pharmacy and patient whether a prescription drug was manufactured or compounded in a foreign country; whether the prescription was approved by the federal food and drug administration foreign drug inspection program; requires the date of the last inspection of such prescription drug by the federal food and drug administration foreign drug inspection program; requires certain labelling on such drugs.
Last Action
referred to health
5/29/2024
Committee Referrals
Health5/29/2024
Full Bill Text
No bill text available